Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

development of KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, August 19, and November 12, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of th
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2015)... March 12, 2015 IriTech, a leading iris ... of the Texas Instruments Design Network, announced today that ... demonstrated its IriShield USB MK2120U device during a launching ... pension distribution. The iris scanner is ... marketed in India through its ...
(Date:3/11/2015)... , March 11, 2015   The Sync ... platform to scientifically measure and harness music to ... real-time biometrics and objective measurements of physiology, enabling ... at scale in large populations. It is designed ... and clinicians perform rigorous studies and accelerate the ...
(Date:3/5/2015)... In Brazil , cloud computing is fast ... and 42 percent planning to invest in them by the ... the companies will be investing in these solutions for the ... the region are currently opting for the private cloud model, ... attention in the coming years. This trend is in line ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... new flame-retardant products are showing up in the ... study by researchers at Indiana University Bloomington. ... & Technology, reports on concentrations of two compounds ... Lakes region between 2008 and 2010. Authors are ...
... GALVESTON, Dec. 13, 2011 Stillbirth is associated with ... or at the start of pregnancy, including prior pregnancy ... obesity and smoking. These findings are the result of ... the December 14th issue of the Journal of ...
... for their bright, long-lasting, and colorful leaves, are ... plants. In Florida, where more than 95% of ... continuously working to develop new varieties to satisfy ... Harbaugh and Natalia A. Peres from the University ...
Cached Biology News:Study finds increasing atmospheric concentrations of new flame retardants 2Risk of stillbirth associated with factors known early in pregnancy 2
(Date:3/30/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), the ... and culture shaping worldwide, today  announced that ... its global Healthcare and Life Sciences practice. As ... will lead a team of more than 80 partners, principals ... and Asia serving clients in the ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015 /PRNewswire/ ... 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... a leading developer and manufacturer of fully functioning human ... that the two companies have entered into a definitive ... tender offer to be followed by a second step ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... ... 20-21, 2010 in Arlington, VA, will discuss practical approaches to President Obama’s challenges to ... ... said we “failed to connect the dots” on the Christmas bomber in his recent ...
... , , SAN DIEGO, Jan. 11 BioMed ... that its operating partnership subsidiary, BioMed Realty, L.P., has completed ... due 2030 (the "Notes"). The company also announced that the ... to cover over-allotments, resulting in a total sale of $180 ...
... , , , BANGALORE, India, January ... Discovery and Development,solution provider, a subsidiary of Jubilant Organosys Ltd, ... co-marketing agreement to,provide screening solutions, with DiscoveRx Corporation (Fermont, USA), ... Kinases,NHR and Proteases. , This agreement ...
Cached Biology Technology:NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 3DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services 2DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services 3
...
...
...
... Slotted migration Chamber lid allows easy gel ... One-touch connectors for easy set up between power ... prevents current flow if the lid is removed ... and durability., Remote control can be ...
Biology Products: